



**Interfacility Transport (IFT) Service Provider Dispatch and Transport Criteria**

**IFT-BLS Dispatch Criteria**

Patients transported by Interfacility Transport Basic Life Support (IFT-BLS) must not require services that are beyond the "OCEMS EMT Scope of Practice" (OCEMS Policy # 315.00). The IFT-BLS service transport level is suitable if deemed the appropriate level of transport by a physician or attending physician designated allied health professional and within the following parameters of action:

1. Obtain and monitor blood pressure, pulse, respiration status, blood oxygen saturation level, level of consciousness, pain level, skin signs, temperature, and pupil status.
2. Use and monitor the following airway and breathing aids:
  - Nasopharyngeal airway
  - Suction devices
  - Administer oxygen utilizing nasal cannula or mask devices
3. Use stretchers and body immobilization devices
4. Monitor intravenous lines delivering at a sending facility preset rate:
  - Normal saline, Ringers Lactate, Dextrose 5% with half normal saline
  - Folic acid
  - Thiamine
  - Multivitamins
  - Antibiotic, antifungal, and antiviral agents
  - Total Parenteral Nutrition (TPN)
5. Transport patients with subcutaneous or patient-operated infusion pumps delivering medications including but not limited to:
  - Insulin
  - Morphine sulfate
6. Transport patients with prescribed transdermal medication patches previously placed on the skin including but not limited to:
  - Fentanyl
  - Nitrobid
  - Nitroglycerin (patch or paste)
  - Clonidine
7. Transport patients, deemed appropriate for BLS by the transferring physician with any of the following:
  - Nasogastric tubes
  - Heparin or saline locks
  - Hemodialysis shunts
  - Colostomy sites
  - Foley catheters
  - Continuous flow oxygen
  - Cardiac pacemakers (implanted)
  - Gastrostomy tubes
  - Tracheostomy tubes
  - Established central lines without infusing solutions
  - Urostomy sites
  - Enteric feeding tubes
  - Thoracostomy (chest) tubes that are secured and sealed
  - Surgical drain suction devices with preset parameters

Approved:

Review Dates: 8/15; 11/18; 10/19  
Initial Release Date: 10/24/2019  
Final Implementation Date: 10/24/2019  
OCEMS copyright © 2019



**Interfacility Transport (IFT) Service Provider Dispatch and Transport Criteria**

- Automatic internal defibrillators (implanted)

**IFT-ALS Dispatch Criteria**

The IFT-ALS service transport level is appropriate if deemed the appropriate level of transport by a physician or attending physician designated allied health professional. A currently accredited OCEMS IFT-ALS Provider may be dispatched to any of the following advanced life support situations:

1. Transport of acute stroke, cardiac, burn, replantation, or trauma patients from an Orange County acute care hospital to a specialty center. Patient transfer must be deemed ALS level appropriate by the sending physician.
2. Transport of patients that have the following intravenous solutions infused by an external pump at a flow rate predetermined by the transferring physician:
  - Amiodarone\*
  - Benzodiazepines [including midazolam (Versed), lorazepam (Ativan), diazepam (Valium)]
  - Dopamine
  - Fentanyl
  - Heparin\*
  - Insulin
  - Lidocaine
  - Nitroglycerin\*
  - Normal saline, Ringers Lactate, dextrose solutions, solutions with KCL (potassium chloride) at no more than 20 meq/liter.
  - Magnesium Sulfate
  - Morphine
  - Sodium Bicarbonate
  - Tissue Plasminogen Activator (tPA)\*
  - Total Parenteral Nutrition (TPN) / Intravenous Lipid Emulsions

\* Orange County EMS Agency Optional Scope

IFT-ALS paramedics may discontinue any of above infusions if there is evidence of patient decompensation during transport.

3. Transport of a patient requiring cardiac monitoring with approval for use of any appropriate IFT-ALS Cardiac Standing Order (OCEMS # IFT-SO-2).
4. Transport of a patient who has had a hypoglycemic reaction and may require blood glucose monitoring with potential glucose administration.
5. Transport of a patient requiring albuterol administration while in route.

Approved:

*Carl Schultz, MD*

Review Dates: 8/15; 11/18; 10/19  
Initial Release Date: 10/24/2019  
Final Implementation Date: 10/24/2019  
OCEMS copyright © 2019

